Factors related to loss of residual renal function in peritoneal dialysis;Factores relacionados con la pérdida de función renal residual en diálisis peritoneal

Nefrologia

Volumn 28, Issue SUPPL. 6, 2008, Pages 39-44

  Coronel, Francisco ^a   Perez Flores I ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Peritoneal dialysis; Residual renal function; Survival

Indexed keywords

CONFERENCE PAPER; DRUG EFFECT; HUMAN; KIDNEY; MORTALITY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; RISK FACTOR; SURVIVAL RATE;

HUMANS; KIDNEY; PERITONEAL DIALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 55949109717     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study group. J Am Soc Nephrol 1996; 7: 198-207.
2. Maiorca R, Brunori G, Zubani R y cols. Predictive value of dialysis adecuacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995; 10: 2295-2305.
3. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162.
4. Paniagua R, Amato D, Vonesh E y cols. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
5. Coronel F, Cigarrán S, Herrero JA, Martín P. Función renal medida por GFR-MDRD-7 en diabéticos al iniciar diálisis peritoneal y su influencia en la supervivencia. Nefrología 2004; 24 (V): 53.
6. Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT. Quality of life over time in dialysis: the Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int 1999; 56: 720-728.
7. Moist LM, Port FK, Orzol SM y cols. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564.
8. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814-1818.
9. Termorshuizen F, Korevaar JC, Dekker FW y cols. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 1293-1302.
10. Wang AY, Woo J, Wang M y cols. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005; 20: 396-403.
11. Wang AY, Wang M, Woo J y cols. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639-647.
12. Wang AY, Woo J, Lan CW y cols. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14: 1871-1879.
13. Chung SH, Heimburger O, Stenvinkel P y cols. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18: 590-597.
14. Wang AY, Wang M, Woo J y cols. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 2186-2194.
15. Witko-Sarsat V, Friedlander M, Nguyen KT y cols. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Inmunol 1998; 161: 2524-2532.
16. Shin SK, Noh H, Kang SW y cols. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19: 138-142.
17. Pérez-Flores I, Coronel F, Cigarrán S y cols. Relationship between residual renal function, inflammation and anemia in peritoneal dialysis. Adv Perit Dial 2007; 23: 140-143.
18. Wang AY, Sea MM, Tang N y cols. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patient: J Am Soc Nephrol 2004; 15: 3134-3143.
19. Coronel F, Pérez-Flores I, Calvo N y cols. Impact of cardiovascular events on residual renal function during the first year of peritoneal dialysis. Perit Dial Int 2007; 27: 454-456.
20. Shinghal MK, Bhaskaran S, Vidgen E y cols. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000; 20: 429-438.
21. Lui SL, Cheng SW, Ng F y cols. Cefazolin plus metilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int 2005; 68: 2375-2380.
22. Han SH, Lee SC, Ahn SV y cols. Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2007; 22: 2653-2658.
23. Gallar P, Ortega O, Carreño A y cols. Rate of decline in residual renal function is equal in CAPD and automated peritoneal dialysis patients. Perit Dial Int 2000; 20: 803-805.
24. Holley JL, Aslam N, Bernardini J y cols. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit Dial Int 2001; 21: 302-305.
25. Hufnagel G, Michel C, Queffeulou G y cols. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14: 1224-1228.
26. Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology 2003; 8: 184-191.
27. Rodríguez-Carmona A, Pérez-Fontán M, García-Naveiro R y cols. Compared time profiles of ultrafiltration, sodium renoval, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44: 132-145.
28. Johnson DW, Mudge DW, Sturtevan JM y cols. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23: 276-283.
29. Adachi Y, Nishio A, Ikegami T. Tidal automated peritoneal dialysis preserves residual renal function better than non tidal automated peritoneal dialysis. Adv Perit Dial 2007; 23: 98-101.
30. Berlanga JR, Marrón B, Reyero A y cols. Peritoneal dialysis retardation of progression of advanced renal failure. Perit Dial Int 2002; 22: 239-242.
31. Chung SH, Heimburger O, Stenvinkel P y cols. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001; 16: 2240-2245.
32. Wang T, Heimburger O, Cheng HH y cols. Does a high peritoneal transport rate reflect a state of chronic inflammation? Perit Dial Int 1999; 19: 17-22.
33. Shemin D, Maaz D, St. Pierre D y cols. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999; 34: 14-20.
34. Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41: 670-675.
35. Wang AY-M, Lai K-N. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69: 1726-1732.
36. Dittrich E, Puttinger H, Schillinger M y cols. Effect of radio contrast media on residual renal function in peritoneal dialysis patients - a prospective study. Nephrol Dial Transplant 2006; 21: 1334-1339.
37. Tepel M, Van der Giet M, Schwarzfeld C y cols. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
38. Moranne O, Willoteaux S Pagnied D y cols. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant 2006; 21: 1040-1045.
39. Jansen MA, Hart AA, Korevaar JC y cols. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053.
40. Gunal AI, Duman S, Oskahya M y cols. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 588-593.
41. Li PK, Chow KM, Wong TY y cols. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. Ann Intern Med 2003; 139: 105-112.
42. Suzuki H, Kanno Y, Sugahara S y cols. Effect of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056-1064.
43. Coronel F, Berni A, Cigarrán S y cols. Effect of angiotensin II receptor blocker (Irbesartan) on peritoneal membrane functions. Adv Perit Dial 2004; 20: 27-30.
44. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59: 1128-1133.
45. Mak SK, Lo KY, Lo MW y cols. High dose furosemide in the preservation of residual renal function in patients newly started on CAPD - a prospective study. PDI 2007; 27 (Supl. 4): 57.
46. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-523.
47. Otte K, González MT, Bajo MA y cols. Clinical experience with a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dialysis solution. Perit Dial Int 2003; 23: 138-145.
48. Davies SJ, Woodrow G, Donovan K y cols. Icodextrine improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344.
49. Adachi Y, Nakagawa Y, Nishio A. Icodextrine preserves residual renal function in patients treated with automated peritoneal dialysis. Perit Dial Int 2006; 26: 405-407.
50. Konings CJ, Kooman JP, Gladziwa U y cols. A decline in residual glomerular filtration during the use of icodextrina may be due to underhidration. Kidney Int 2005; 67: 1190-1191.
51. Williams JD, Topley N, Craig KJ y cols. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418.
52. Szeto CC, Chow KM, Lam CW y cols. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products - a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22: 552-559.
53. Montenegro J, Saracho RM, Martínez IM y cols. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94.
54. Montenegro J, Saracho R, Gallardo YI y cols. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incident of CAPD peritonitis. Nephrol Dial Transplant 2007; 22: 1703-1708.
55. Le Poole CY, Van Ittersum FJ, WeijmerMC y cols. Clinical effects of a peritoneal regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20: 170-176.
56. Rodríguez-Carmona A, Pérez Fontán M, García López E y cols. Use of icodextrine during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007; 27: 260-266.
57. Fan SLS, Pile T, Punzalan S y cols. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200-206.
58. Caravaca F, Domínguez C, Arrobas M. Predictors of loss of residual renal function in peritoneal dialysis patients. Perit Dial Int 2002; 22: 414-417.